SearchClear
Mobile App

Google Play Apple Store
Patient-Focused Strategies to Effectively Diagnose, Treat, and Manage NF1-PN
AMA/ABS/ANCC- Video Lecture Library

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Click ‘Continue to Activity’ to begin and claim up to
1.0 AMA, ABS, or ANCC credit/contact hour(s) after completion
Angela Hirbe, MD, PhD
Angela Hirbe, MD, PhD
Associate Professor of Medicine and Pediatrics Director
Adult Neurofibromatosis Clinical Program Division of Oncology Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri
 

Patient-Focused Strategies to Effectively Diagnose, Treat, and Manage NF1-PN
AMA/ABS/ANCC- Video Lecture Library
Angela Hirbe, MD, PhD
Angela Hirbe, MD, PhD
Associate Professor of Medicine and Pediatrics Director
Adult Neurofibromatosis Clinical Program Division of Oncology Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Click ‘Continue to Activity’ to begin and claim up to
1.0 AMA, ABS, or ANCC credit/contact hour(s) after completion
Angela Hirbe, MD, PhD
Angela Hirbe, MD, PhD
Associate Professor of Medicine and Pediatrics Director
Adult Neurofibromatosis Clinical Program Division of Oncology Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri


 


 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.

Overview

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Patient-Focused Strategies to Effectively Diagnose, Treat, and Manage NF1-PN

AMA/ABS/ANCC- Video Lecture Library

Angela Hirbe, MD, PhD
Angela Hirbe, MD, PhD
Associate Professor of Medicine and Pediatrics Director
Adult Neurofibromatosis Clinical Program Division of Oncology Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri
 


20
Supported by an independent educational grant from Alexion, AstraZeneca Rare Disease

Approved Children’s Tumor Foundation Educational Partner

Launch/Release Date: October 15, 2025
Activity Expiration Date: September 30, 2026

Streamlined
8000
LectureLibrary_NF1-PN _2025(1730x162).gif
True
  • Neurology
  • Archives
Neurology
Change Settings